Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...

J.P. Morgan analyst Eric Joseph maintained a Sell rating on Novavax (NVAX – Research Report) yesterday and set a price target of $9.00. Eric Joseph has given his Sell rating due to a combination of ...

Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...

Novavax received clearance from the FDA to move forward with phase 3 clinical trials for its COVID-19-influenza combination (CIC) and standalone influenza vaccines. The FDA lifted a clinical hold that ...

Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected ...

With flu season underway and new, developing COVID-19 strains, health professionals continue to stress the importance of receiving an updated vaccine. On Oct. 23, the Centers for Disease Control ...

An abundance of evidence indicates the mRNA COVID-19 vaccines are remarkably safe and work well to protect against severe ...

COVID-19 vaccine DNA contamination claims aren't new, but have resurfaced in the wake of a Canadian study that some ...

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or “the Company ...

About a week later, the agency authorized an updated version of Novavax’s protein subunit vaccine for people 12 years and older. The mRNA vaccines specifically target KP.2, a subvariant of JN.